About Pipeline Strategy Events Investors News Contact
  By the end of 1Q 2014, ACT expects to have successfully completed raising an additional $5 million to advanced its novel anti-cancer product pipeline. To date, ACT has raised over $13 million and built a promising pipeline of potential breakthrough anti-cancer products entering human clinical trials.

ACT business model is to partner with commercial pharmaceutical companies prior to or at the completion of Phase 1 human clinical trials.